Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Q2 Print
July 29, 2026 9:27 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
